Oesophageal adenocarcinoma is associated with a deregulation in the MYC/MAX/MAD network

British Journal of Cancer

Volumn 98, Issue 12, 2008, Pages 1985-1992

  Boult, J K R ^a   Taniere P ^a   Hallissey, M T ^b   Campbell, M J ^c   Tselepis, C ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Barrett's metaplasia; c MYC; MAD; Oesophageal adenocarcinoma

Indexed keywords

BUB1 RELATED PROTEIN; MAX PROTEIN; MESSENGER RNA; MYC PROTEIN; PROTEIN MAD1; PROTEIN MAD2; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR MXI1;

ARTICLE; BARRETT ESOPHAGUS; CELL LINE; CELL PROLIFERATION; CONTROLLED STUDY; ESOPHAGEAL ADENOCARCINOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; QUANTITATIVE ASSAY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ADENOCARCINOMA; BASIC HELIX-LOOP-HELIX LEUCINE ZIPPER TRANSCRIPTION FACTORS; BLOTTING, WESTERN; CELL LINE; ESOPHAGEAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MYC; HUMANS; IMMUNOHISTOCHEMISTRY; REPRESSOR PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 44949251688     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604398     Document Type: Article

References (53)

1. Ayer DE, Kretzner L, Eisenman RN (1993) Mad: a heterodimeric partner for Max that antagonizes Myc transcriptional activity. Cell 72: 211-222
2. Bartsch D, Peiffer SL, Kaleem Z, Wells Jr SA, Goodfellow PJ (1996) Mxi1 tumor suppressor gene is not mutated in primary pancreatic adenocarcinoma. Cancer Lett 102: 73-76
3. Benson LQ, Coon MR, Krueger LM, Han GC, Sarnaik AA, Wechsler DS (1999) Expression of MXI1, a Myc antagonist, is regulated by Sp1 and AP2. J Biol Chem 274: 28794-28802
4. Berberich S, Hyde-DeRuyscher N, Espenshade P, Cole M (1992) Max encodes a sequence-specific DNA-binding protein and is not regulated by serum growth factors. Oncogene 7: 775-779
5. Bernasconi NL, Wormhoudt TA, Laird-Offringa IA (2000) Post-transcriptional deregulation of myc genes in lung cancer cell lines. Am J Respir Cell Mol Biol 23: 560-565
6. Blackwood EM, Eisenman RN (1991) Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc. Science 251: 1211-1217
7. Bollschweiler E, Wolfgarten E, Gutschow C, Holscher AH (2001) Demographic variations in the rising incidence of esophageal adenocarcinoma in white males. Cancer 92: 549-555
8. Brookes MJ, Hughes S, Turner FE, Reynolds G, Sharma N, Ismail T, Berx G, McKie AT, Hotchin N, Anderson GJ, Iqbal T, Tselepis C (2006) Modulation of iron transport proteins in human colorectal carcinogenesis. Gut 55: 1449-1460
9. Chen J, Willingham T, Margraf LR, Schreiber-Agus N, DePinho RA, Nisen PD (1995) Effects of the MYC oncogene antagonist, MAD, on proliferation, cell cycling and the malignant phenotype of human brain tumour cells. Nat Med 1: 638-643
10. Chiariello M, Marinissen MJ, Gutkind JS (2001) Regulation of c-myc expression by PDGF through Rho GTPases. Nat Cell Biol 3: 580-586
11. Chin L, Schreiber-Agus N, Pellicer I, Chen K, Lee HW, Dudast M, Cordon-Cardo C, DePinho RA (1995) Contrasting roles for Myc and Mad proteins in cellular growth and differentiation. Proc Natl Acad Sci USA 92: 8488-8492
12. Croft J, Parry EM, Jenkins GJ, Doak SH, Baxter JN, Griffiths AP, Brown TH, Parry JM (2002) Analysis of the premalignant stages of Barrett's oesophagus through to adenocarcinoma by comparative genomic hybridization. Eur J Gastroenterol Hepatol 14: 1179-1186
13. Cultraro CM, Bino T, Segal S (1997) Regulated expression and function of the c-Myc antagonist, Mad1, during a molecular switch from proliferation to differentiation. Curr Top Microbiol Immunol 224: 149-158
14. Dang CV (1999) c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol Cell Biol 19: 1-11
15. Di Martino E, Wild CP, Rotimi O, Darnton JS, Olliver RJ, Hardie LJ (2006) IGFBP-3 and IGFBP-10 (CYR61) up-regulation during the development of Barrett's oesophagus and associated oesophageal adenocarcinoma: potential biomarkers of disease risk. Biomarkers 11: 547-561
16. Doak SH, Jenkins GJ, Parry EM, D'Souza FR, Griffiths AP, Toffazal N, Shah V, Baxter JN, Parry JM (2003) Chromosome 4 hyperploidy represents an early genetic aberration in premalignant Barrett's oesophagus. Gut 52: 623-628
17. Engstrom LD, Youkilis AS, Gorelick JL, Zheng D, Ackley V, Petroff CA, Benson LQ, Coon MR, Zhu X, Hanash SM, Wechsler DS (2004) Mxi1-0, an alternatively transcribed Mxi1 isoform, is overexpressed in glioblastomas. Neoplasia 6: 660-673
18. Grandori C, Cowley SM, James LP, Eisenman RN (2000) The Myc/Max/Mad network and the transcriptional control of cell behavior. Annu Rev Cell Dev Biol 16: 653-699
19. Gray IC, Phillips SM, Lee SJ, Neoptolemos JP, Weissenbach J, Spurr NK (1995) Loss of the chromosomal region 10q23-25 in prostate cancer. Cancer Res 55: 4800-4803
20. Hage M, Siersema PD, van Dekken H, Steyerberg EW, Dees J, Kuipers EJ (2004) Oesophageal cancer incidence and mortality in patients with long-segment Barrett's oesophagus after a mean follow-up of 12.7 years. Scand J Gastroenterol 39: 1175-1179
21. Han S, Park K, Kim HY, Lee MS, Kim HJ, Kim YD, Yuh YJ, Kim SR, Suh HS (2000) Clinical implication of altered expression of Mad1 protein in human breast carcinoma. Cancer 88: 1623-1632
22. Hourihan RN, O'Sullivan GC, Morgan JG (2003) Transcriptional gene expression profiles of oesophageal adenocarcinoma and normal oesophageal tissues. Anticancer Res 23: 161-165
23. Hughes SJ, Nambu Y, Soldes OS, Hamstra D, Rehemtulla A, Iannettoni MD, Orringer MB, Beer DG (1997) Fas/APO-1 (CD95) is not translocated to the cell membrane in esophageal adenocarcinoma. Cancer Res 57: 5571-5578
24. Hurlin PJ, Foley KP, Ayer DE, Eisenman RN, Hanahan D, Arbeit JM (1995a) Regulation of Myc and Mad during epidermal differentiation and HPV-associated tumorigenesis. Oncogene 11: 2487-2501
25. Hurlin PJ, Queva C, Koskinen PJ, Steingrimsson E, Ayer DE, Copeland NG, Jenkins NA, Eisenman RN (1995b) Mad3 and Mad4: novel Max-interacting transcriptional repressors that suppress c-myc dependent transformation and are expressed during neural and epidermal differentiation. EMBO J 14: 5646-5659
26. Jankowski JA, Harrison RF, Perry I, Balkwill F, Tselepis C (2000) Barrett's metaplasia. Lancet 356: 2079-2085
27. Kawamata N, Sugimoto KJ, Sakajiri S, Oshimi K, Koeffler HP (2005) Mxi1 isoforms are expressed in hematological cell lines and normal bone marrow. Int J Oncol 26: 1369-1375
28. Kuczyk MA, Serth J, Bokemeyer C, Schwede J, Herrmann R, Machtens S, Grunewald V, Hofner K, Jonas U (1998) The MXI1 tumor suppressor gene is not mutated in primary prostate cancer. Oncol Rep 5: 213-216
29. Lagergren J (2005) Adenocarcinoma of oesophagus: what exactly is the size of the problem and who is at risk? Gut 54(Suppl 1): i1-i5
30. Larsson LG, Pettersson M, Oberg F, Nilsson K, Luscher B (1994) Expression of mad, mxi1, max and c-myc during induced differentiation of hematopoietic cells: opposite regulation of mad and c-myc. Oncogene 9: 1247-1252
31. Littlewood TD, Hancock DC, Danielian PS, Parker MG, Evan GI (1995) A modified oestrogen receptor ligand-binding domain as an improved switch for the regulation of heterologous proteins. Nucleic Acids Res 23: 1686-1690
32. Lymboussaki A, Kaipainen A, Hatva E, Vastrik I, Jeskanen L, Jalkanen M, Werner S, Stenback F, Alitalo R (1996) Expression of Mad, an antagonist of Myc oncoprotein function, in differentiating keratinocytes during tumorigenesis of the skin. Br J Cancer 73: 1347-1355
33. Martel C, Lallemand D, Cremisi C (1995) Specific c-myc and max regulation in epithelial cells. Oncogene 10: 2195-2205
34. Nesbit CE, Tersak JM, Prochownik EV (1999) MYC oncogenes and human neoplastic disease. Oncogene 18: 3004-3016
35. Osterland CK, Wilkinson RD, St Louis EA (1990) Expression of c-myc protein in skin and synovium in psoriasis and psoriatic arthritis. Clin Exp Rheumatol 8: 145-150
36. Pelengaris S, Khan M, Evan G (2002) c-MYC: more than just a matter of life and death. Nat Rev Cancer 2: 764-776
37. Pelengaris S, Littlewood T, Khan M, Elia G, Evan G (1999) Reversible activation of c-Myc in skin: induction of a complex neoplastic phenotype by a single oncogenic lesion. Mol Cell 3: 565-577
38. Pelengaris S, Rudolph B, Littlewood T (2000) Action of Myc in vivo - proliferation and apoptosis. Curr Opin Genet Dev 10: 100-105
39. Queva C, Hurlin PJ, Foley KP, Eisenman RN (1998) Sequential expression of the MAD family of transcriptional repressors during differentiation and development. Oncogene 16: 967-977
40. Royds JA, Sharrard RM, Wagner B, Polacarz SV (1992) Cellular localisation of c-myc product in human colorectal epithelial neoplasia. J Pathol 166: 225-233
41. Salghetti SE, Kim SY, Tansey WP (1999) Destruction of Myc by ubiquitin-mediated proteolysis: cancer-associated and transforming mutations stabilize Myc. EMBO J 18: 717-726
42. Sant M, Aareleid T, Berrino F, Bielska Lasota M, Carli PM, Faivre J, Grosclaude P, Hedelin G, Matsuda T, Moller H, Moller T, Verdecchia A, Capocaccia R, Gatta G, Micheli A, Santaquilani M, Roazzi P, Lisi D, the EUROCARE Working Group (2003) EUROCARE-3: survival of cancer patients diagnosed 1990-94-results and commentary. Ann Oncol 14: v61-v118
43. Schmidt MK, Meurer L, Volkweis BS, Edelweiss MI, Schirmer CC, Kruel CDP, Gurski RR (2007) c-Myc overexpression is strongly associated with metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. Diseases Esophagus 20: 212-216
44. Schuhmacher M, Kohlhuber F, Holzel M, Kaiser C, Burtscher H, Jarsch M, Bornkamm GW, Laux G, Polack A, Weidle UH, Eick D (2001) The transcriptional program of a human B cell line in response to Myc. Nucl Acids Res 29: 397-406
45. Solaymani-Dodaran M, Logan RF, West J, Card T, Coupland C (2004) Risk of oesophageal cancer in Barrett's oesophagus and gastro-oesophageal reflux. Gut 53: 1070-1074
46. Tselepis C, Morris CD, Wakelin D, Hardy R, Perry I, Luong QT, Harper E, Harrison R, Attwood SEA, Jankowski JAZ (2003) Upregulation of the oncogene c-myc in Barrett's adenocarcinoma: induction of c-myc by acidified bile acid in vitro. Gut 52: 174-180
47. van Dekken H, Vissers K, Tilanus HW, Kuo WL, Tanke HJ, Rosenberg C, Ijszenga M, Szuhai K (2006) Genomic array and expression analysis of frequent high-level amplifications in adenocarcinomas of the gastro-esophageal junction. Cancer Genet Cytogenet 166: 157-162
48. Vastrik I, Kaipainen A, Penttila TL, Lymboussakis A, Alitalo R, Parvinen M, Alitalo K (1995) Expression of the mad gene during cell differentiation in vivo and its inhibition of cell growth in vitro. J Cell Biol 128: 1197-1208
49. Walch AK, Zitzelsberger HF, Bruch J, Keller G, Angermeier D, Aubele MM, Mueller J, Stein H, Braselmann H, Siewert JR, Hofler H, Werner M (2000) Chromosomal imbalances in Barrett's adenocarcinoma and the metaplasia-dysplasia- carcinoma sequence. Am J Pathol 156: 555-566
50. Walker W, Zhou ZQ, Ota S, Wynshaw-Boris A, Hurlin PJ (2005) Mnt-Max to Myc-Max complex switching regulates cell cycle entry. J Cell Biol 169: 405-413
51. Wechsler DS, Shelly CA, Petroff CA, Dang CV (1997) MXI1, a putative tumor suppressor gene, suppresses growth of human glioblastoma cells. Cancer Res 57: 4905-4912
52. Yin XY, Gupta K, Han WP, Levitan ES, Prochownik EV (1999) Mmip-2, a novel RING finger protein that interacts with mad members of the Myc oncoprotein network. Oncogene 18: 6621-6634
53. Zervos AS, Gyuris J, Brent R (1993) Mxi1, a protein that specifically interacts with Max to bind Myc-Max recognition sites. Cell 72: 223-232